2017 Agenda

  • 1:00 pm

  • Registration

  • 1:30 pm

  • Co-Chair’s Opening Remarks

    Axel Hoos, MD, PhD
    SVP, Oncology R&D, GlaxoSmithKline

    James Gulley, MD, PhD
    Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute


  • Plenary Session: Preclinical Science

    Plenary Chairperson:
    Patrick Mayes, PhD
    Director & Early Development Leader, GlaxoSmithKline

  • 1:40 pm

  • Plenary Keynote: Clonal Selection of Neo-Antigen Biology

    Sergio Quezada, PhD
    Head, Immune Regulation and Tumor Immunotherapy Group, University College London Cancer Institute 

  • 2:10 pm

  • Immuno-Oncology Agonist Antibodies

    Patrick Mayes, PhD
    Director & Early Development Leader, GlaxoSmithKline

  • 2:30 pm

  • Sequencing of Combination Agents

    Charles Drake, MD, PhD
    Director, Genitourinary Oncology / Co-Director Immunotherapy Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center

  • 2:50 pm

  • Biological Insights into Human Tumor Immunology from Clinical Trials Using Checkpoint Inhibitors and Combinations

    Priti Hegde, PhD
    Anti-angiogenesis and Cancer Immunotherapy Franchises Biomarker Lead, Oncology Biomarkers, Genentech

  • 3:10 pm

  • Identifying Factors Regulating T cell and Tumor Interactions with the Jedi

    Brian Brown, PhD
    Associate Professor, Icahn School of Medicine at Mount Sinai

  • 3:30 pm

  • Isotope Selective Cancer Immunotherapy

    Peter Novak, PhD
    CEO, Vector Vitale

  • 3:40 pm

  • Networking Break


  • Plenary Session: Translational Science and New Technologies

    Plenary Chairperson:
    Renee Donahue, PhD
    Scientist, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute

  • 4:10 pm

  • Multi-Color Flow Cytometry Assay As a Predictive Biomarker

    Renee Donahue, PhD
    Scientist, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute

  • 4:30 pm

  • Development of a Novel Phenotypic Assay Based Platform for Therapy Selection and Understanding the Biology of Tumor Immune Response

    Pradip Majumder, PhD
    Chief Scientific Officer, Mitra Biotech

  • 4:50 pm

  • The Increasingly Critical Role of Predictive Clinical Biomarkers in Cancer Immunotherapy

    Alessandra Cesano, MD, PhD
    Chief Medical Officer, NanoString Technologies

  • 5:10 pm

  • T Cell Receptor Diversity as a Predictor of Clinical Outcomes

    Lanny Kirsch, MD
    SVP, Translational Medicine, Adaptive Biotechnologies

  • 5:30 pm

  • Correlation Between Levels of PD-L1 Expression and Genomic Mutations in Various Types of Tumors

    Maher Albitar, MD
    SVP, Chief Medical Officer and Director of Research and Development, NeoGenomics Laboratories

  • 5:50 pm

  • Directing Innate and Adaptive Immunity to Eliminate Tumor Cells

    Adi Hoess, MD, PhD
    CEO, Affimed

  • 6:10 pm

  • Day Concludes

2017 Agenda

  • 8:15 am

  • Registration

  • 9:00 am

  • Co-Chair’s Opening Remarks

    Axel Hoos, MD, PhD
    SVP, Oncology R&D, GlaxoSmithKline

    James Gulley, MD, PhD
    Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute


  • Plenary Session: Trends & Collaborations in the IO Space

    Plenary Chairperson:
    Ramy Ibrahim, MD
    VP and Head of R&D, Parker Institute for Cancer Immunotherapy

  • 9:15 am

  • Parker Institute IO Initiatives

    Ramy Ibrahim, MD
    VP and Head of R&D, Parker Institute for Cancer Immunotherapy

  • 9:35 am

  • Breakfast and Networking Break

  • 10:15 am

  • Partnership for Accelerating Cancer Therapies (PACT)

    David Wholley, MPhil
    Director, Research Partnerships Division, Foundation for the National Institutes of Health

  • 10:35 am

  • Cancer Research Institute’s Clinical Trial Initiatives

    Jill O’Donnell-Tormey, PhD
    CEO and Director of Scientific Affairs, Cancer Research Institute

  • 10:55 am

  • Elements of Immunity: Beyond the Cancer Immunity Cycle and the Future of Cancer Immunotherapy

    Daniel Chen, MD, PhD
    VP, Global Head of Cancer Immunotherapy Development, Genentech

  • 11:15 am

  • Panel: Trends and Collaborations in the IO Space

    Moderator:
    Axel Hoos, MD, PhD
    SVP, Oncology R&D, GlaxoSmithKline

    Panelists:
    Ramy Ibrahim, MD
    VP and Head of R&D, Parker Institute for Cancer Immunotherapy

    Jill O’Donnell-Tormey, PhD
    CEO and Director of Scientific Affairs, Cancer Research Institute

    Daniel Chen, MD, PhD
    VP, Global Head of Cancer Immunotherapy Development, Genentech

    David Wholley, MPhil
    Director, Research Partnerships Division, Foundation for the National Institutes of Health

  • 12:00 pm

  • Grab and Go Lunch


  • Plenary Session: Clinical Advancements Part 1

    Plenary Chairperson:
    James Gulley, MD, PhD
    Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute

  • 1:05 pm

  • Expansion of PD-1 Indications and Longer Term Outcomes

    Roy Baynes, MD, PhD
    SVP and Head, Global Clinical Development, Chief Medical Officer, Merck Research Laboratories

  • 1:25 pm

  • OX40 Clinical Data Across Different Products

    Patrick Hwu, MD
    Head, Division of Cancer Medicine / Department Chair, Melanoma Medical Oncology /Department Chair, Sarcoma Medical Oncology, MD Anderson Cancer Center

  • 1:45 pm

  • Oncolytic Virus Checkpoint Combinations

    Roger Sidhu, MD
    GPGM, Oncology Early Development, Amgen

  • 2:05 pm

  • Combination of Checkpoint with Chemotherapy

    Julie Brahmer, MD
    Interim Director / Director, Thoracic Oncology / Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University  

  • 2:25 pm

  • Selection of Patients for Monotherapy and Combination Therapy; Triage of Combination Therapies and Progress in Evaluation of Combination Therapies

    David Kaufman, MD, PhD
    Executive Director, Translational Immuno-Oncology Lead, Oncology Clinical Research, Merck Research Labs

  • 2:45 pm

  • Effectively Delivering IO Therapies to Patients with Rare or Hard-to-find Tumor Types

    Noelle Gaskill, MBA
    Senior Director, Research Operations, US Oncology Research

    Adam H. Kinsey
    Clinical Research Director – Oncology
    Global Clinical Trial Operations – North America (US – Austin, Texas), Merck Research Laboratories

  • 3:05 pm

  • Afternoon Networking Break

  • 3:35 pm

  • Panel: Addressing Clinical Challenges

    Moderator:
    James Gulley, MD, PhD
    Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute

    Panelists:
    Roy Baynes, MD, PhD
    SVP and Head, Global Clinical Development, Chief Medical Officer, Merck Research Laboratories

    Alessandra Cesano, MD, PhD
    Chief Medical Officer, nanoString Technologies

    Patrick Hwu, MD
    Head, Division of Cancer Medicine/ Department Chair, Melanoma Medical Oncology/ Department Chair, Sarcoma Medical Oncology, MD Anderson Cancer Center

    Robert Millham, MS, MSc
    PharmMed SVP & General Manager, Hematology & Oncology, inVentiv Health


  • Plenary Session: Imaging Methodologies & Techniques for Immunotherapy

    Plenary Chairperson:
    Andrea Perrone, MD
    Associate Vice President, Translational Medicine, Merck Research Labs

  • 4:20 pm

  • Evolution of Imaging Endpoints in Clinical Trials

    Oliver Bohnsack, MD, PhD, MBA
    Senior Director, Scientific and Medical Services, Head of Medical Relations Europe, Head of Oncology, PAREXEL

  • 4:40 pm

  • A New Approach to Modified RECIST 1.1 for Immunotherapeutics (iRECIST)

    Moderator:
    Andrea Perrone, MD
    Associate Vice President, Translational Medicine, Merck Research Labs

    Panelists:
    Elisabeth de Vries, MD, PhD
    Professor, Medical Oncology, University Medical Centre Groningen

    Patricia Keegan, MD
    Director, Division of Oncology Products 2 (DOP2), OHOP, OND, CDER, FDA

    Michael O’Neal, MD
    Chief Medical Officer, Head of Oncology, Bioclinica

    Lawrence Schwartz, MD
    Chief, Radiology Service, Columbia University Medical Center

  • 5:20 pm

  • Novel Imaging Strategies to Evaluate Immune Response in Solid Tumors

    Ron Korn, MD, PhD
    Founder, Chairman and CMO, Imaging Endpoints

  • 5:40 pm

  • Molecular Imaging of Inflammation: Where are We?

    Peter Choyke, MD, FACR
    Molecular Imaging Program Director / Senior Investigator / Head, Imaging Section, Center for Cancer Research, National Cancer Institute

  • 6:00 pm

  • Reception

2017 Agenda

  • 8:00 am

  • Registration

  • 8:30 am

  • Co-Chair’s Opening Remarks

    Axel Hoos, MD, PhD
    SVP, Oncology R&D, GlaxoSmithKline

    James Gulley, MD, PhD
    Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute

  • 8:45 am

  • A Melanoma Survivor Story: T.J. Sharpe’s Immunotherapy Trial Journey

    T.J. Sharpe
    Melanoma Survivor, Advocate and Cancer Blogger


  • Plenary Session: Business Aspects of Immuno-Oncology

    Plenary Chairperson:
    Mark Simon, MBA
    Partner, Torreya Partners

  • 9:10 am

  • Facilitating The Development of New Reimbursement Models

    Lindee Goh, PhD
    Partner, Tapestry Networks

  • 9:40 am

  • Breakfast and Networking Break

  • 10:10 am

  • Addressing and Overcoming Talent Management Challenges in Immuno-Oncology

    Adam Millinger
    Founding Partner, ProMotion Career Management

  • 10:30 am

  • Business Models for Complex Science

    Axel Hoos, MD, PhD
    SVP, Oncology R&D, GlaxoSmithKline

  • 10:50 am

  • Important Business Aspects of IO: Issues and Controversies

     

    Moderator:
    Mark Simon, MBA
    Partner, Torreya Partners

    Panelists:
    Robert Ang, MD, MBA
    Chief Business Officer, Neon Therapeutics

    Jeffrey Bockman, PhD
    VP, Defined Health

    Axel Hoos, MD, PhD
    SVP, Oncology R&D, GlaxoSmithKline

    Jeffrey Legos, PhD
    SVP, Oncology Global Development & Medical Affairs, Novartis Pharmaceuticals

    Chandra Ramanathan, PhD, MBA
    VP and Head, East Coast Innovation Center, Bayer Healthcare

  • 11:30 am

  • Quick-Fire Presentations

    MacroGenics, Inc
    Eric Risser, SVP, Chief Business Officer

    BioLegend
    Ashley Cornett, PhDTechnical Application Scientist

    BeiGene
    Ji Li, PhD, EVP, Global Head of Business Development

    Immodulon Therapeutics
    Laura Rosa Brunet, DSc
    , Chief Scientific Officer

    Miltenyi Biotec GmbH
    Carsten Studte, PhD, Global Product Manager, Cancer Research

    Cytel
    Chuck Gelb,
     Senior Director

  • 12:10 pm

  • Grab and Go Lunch


  • Plenary Session: Clinical Advancements Part 2

    Plenary Chairperson:
    Jeffrey Legos, PhD
    SVP, Oncology Global Development & Medical Affairs, Novartis Pharmaceuticals

  • 1:00 pm

  • Integrating IO into Cancer Modalities

    Jeffrey Legos, PhD
    SVP, Oncology Global Development & Medical Affairs, Novartis Pharmaceuticals

  • 1:20 pm

  • Combination of CTLA4 and PD1 Blockade

    Robert Iannone, MD
    SVP, Head of Immuno-oncology, Global Medicines Development, AstraZeneca

  • 1:40 pm

  • Update on Nivolumab / Ipilimumab First Line Data in NSCLC

    Matthew Hellmann, MD
    Medical Oncologist, Memorial Sloan Kettering Cancer Center

  • 2:00 pm

  • End of Conference